

Patents



Science meets Law...

Boring?

Turgid ?

Irrelevant ?

1. Solagran has a **substantial** patent portfolio.

1. The portfolio is driven by our **core technological patent**, its importance cannot be underestimated, it is the foundation of our intellectual property.

It currently covers the **unique** extraction process for the production of five individual Bioeffectives[®] (A, N, S, R & V) and has the potential to cover further Bioeffectives[®].

3. This position is then bolstered by patents related to the **specific therapeutic** applications of individual Bioeffectives

4. In addition the company holds a technological patent for the **specific extraction** and production method of **Bioeffective[®] I**.

PATENTS – PERCEPTIONS, THE HOW..

1. Takes forever..



2. Costs a fortune..



- No patent is granted with ease, particularly jurisdictions such as the USA and Europe. To achieve granted status any application must be backed by solid science and research.
- Of equal importance is the response strategy employed, a tenacious ability to counter any argument and in some cases – given the revolutionary nature of our science, to actually “teach” the examiner a new way of thinking..
- In all cases the initial filing of our patents takes place in Russia, this is the perfect springboard, allowing the patent to be written in the same language as the science was discovered, whilst the costs are a fraction of those in other jurisdictions. Russia is also a signatory to the international patent cooperation treaty (PCT) thus allowing a seamless transfer to international applications.

**WHY
BOTHER
?**

PROTECTION - THE FORTRESS STRATEGY

“ Essential patent coverage for a company with core RESEARCH and TECHNOLOGY, offering additional protection for resulting products and/or services that will generate revenue.”



EXTRACTING VALUE

One of the biggest challenges faced is putting a dollar figure on a business' intellectual property - How important is the patent's underlying invention? Is it a transformative invention?.. And finally when granted, is there a market for licencing? We believe the answer to all of these key questions is yes, and are now, with numerous grants in place, in a position to engage with potential partners.

CONFIDENCE -THE HIDDEN ADVANTAGE

An incalculable and hidden advantage of our portfolio is the hidden added value to the company the portfolio allows. Adding confidence to research partnerships and commercial collaborations..

SOLAGRAN – INTERNATIONAL PATENT STATUS 2011



SOLAGRAN – INTERNATIONAL PATENT STATUS 2016

1 CANADA
TECHNOLOGICAL

7 RUSSIA
TECHNOLOGICAL
CELL SAP
ALCOHOLICS
DEMENTIA
MAO
TRICH VAG
H PYLORI

4 USA
TECHNOLOGICAL
CELL SAP
DEMENTIA
MAO

6 EUROPE
TECHNOLOGICAL
(Latvia)
CELL SAP
ALCOHOLICS
DEMENTIA
TRICH VAG

1 INDONESIA
H PYLORI

6 AUSTRALIA
TECHNOLOGICAL
CELL SAP
ALCOHOLICS
DEMENTIA
MAO
TRICH VAG

TECHNOLOGICAL
CELL SAP
ALCOHOLICS
DEMENTIA
MAO
TRICH VAG
H PYLORI

The last 5 years in the company's Patent life has been ...

Exciting

Relevant..

Successful ...

We have in addition this year, been granted a further PCT for the treatment of neurological disorders including MS and Parkinsons.

The result of the committment shown by our scientific teams, Russian and Australian attorneys and international associates is evident. What may not be is the scale of the work and complexities of strategy undertaken to facilitate these achievements.

I personally would like to acknowledge the global team that has made this success possible.



Welcome Prenolica

The company that uses unique green technology and world leading science to produce highly effective natural substance with multiple applications collectively trade marked as [Bioeffectives](#).